)
Edge12 Jun 2026
Set in Stone: The Story of Richemont
From a South African tobacco company to Cartier, a deep dive into how Richemont built one of the world's leading hard luxury empires.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals (REGN) investor relations material
Regeneron Pharmaceuticals AGM 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.AGM 2026 summary12 Jun, 2026
Opening remarks and agenda
The meeting was called to order at 10:30 A.M. in a virtual-only format to ensure shareholder participation rights, with senior officers and all directors present or connected by audio.
The agenda and rules of conduct were posted online, and proof of mailing of proxy materials was provided with a quorum confirmed.
Meeting included proposals for election of directors, ratification of the independent accounting firm, and an advisory vote on executive compensation.
Board and executive committee updates
Five Class II directors were nominated for re-election for a one-year term, all currently serving on the board.
CEO presented a strategy and business update, emphasizing innovation and leadership in biotechnology.
Shareholder proposals
Three items were presented for shareholder vote: election of directors, ratification of the independent auditor, and an advisory vote on executive compensation.
EYLEA HD pre-filled syringe regulatory status
Olatorepatide and Praluent obesity trial plans
Regeneron's stance on MFN drug pricing
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Regeneron Pharmaceuticals
- Robust pipeline, strong Q1 growth, and strategic flexibility drive long-term outlook.REGN
Goldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026 - Dupixent and EYLEA HD drive growth as next-gen and oncology assets advance in key markets.REGNBank of America Global Healthcare Conference 202613 May 2026
- Q1 2026 revenue up 19% to $3.61B, strong Dupixent and EYLEA HD sales, new FDA approvals.REGNQ1 202629 Apr 2026
- Earnings and pipeline growth accelerate, supported by innovation and disciplined capital use.REGNTD Cowen 46th Annual Health Care Conference29 Apr 2026
- Board declassification, strong R&D, and robust ESG drive growth and shareholder alignment.REGNProxy filing24 Apr 2026
- Director elections, auditor ratification, and say-on-pay up for vote at June 2026 meeting.REGNProxy filing24 Apr 2026
- Cemdisiran ± pozelimab delivers strong late-stage efficacy and safety, targeting major growth markets.REGNStatus update22 Apr 2026
- Robust pipeline, strong brand growth, and major 2026 milestones drive future outlook.REGN44th Annual J.P. Morgan Healthcare Conference21 Apr 2026
- EYLEA HD and DUPIXENT drive growth as pipeline and strategic initiatives expand into new areas.REGNLeerink Global Healthcare Conference 202611 Mar 2026
Next Regeneron Pharmaceuticals earnings date
Q2 202631 Jul, 2026
Regeneron Pharmaceuticals
Next Regeneron Pharmaceuticals earnings date
Q2 202631 Jul, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage